Elena Ridloff Sells 4,600 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 4,600 shares of the company’s stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $85.42, for a total transaction of $392,932.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total value of $631,738.00.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $85.40 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00. The business has a 50-day moving average price of $81.57 and a 200 day moving average price of $72.00. The firm has a market cap of $6.97 billion, a PE ratio of -23.21 and a beta of 2.28.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The business had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. During the same quarter in the prior year, the company posted ($0.88) EPS. The business’s revenue for the quarter was down 60.8% compared to the same quarter last year. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Key Headlines Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Multiple research firms have raised price targets and reiterated buy/outperform views (Mizuho, Oppenheimer, B. Riley, Leerink, UBS), supporting upside expectations for KYMR. Analyst Upgrades and Targets
• Positive Sentiment: Large institutional holders (Baker Bros., Avoro, Vanguard, Price T. Rowe, BVF) increased positions in recent quarters, signaling continued fund-level conviction in Kymera’s Pegasus degrader platform and pipeline. Institutional Activity
• Neutral Sentiment: Company fundamentals/context: Kymera is a clinical‑stage degrader-focused biotech with a mixed near‑term financial picture (recent quarter missed revenue and EPS estimates). These operational results remain a material background factor for how investors value upcoming clinical and partnership milestones. Earnings and Company Profile
• Negative Sentiment: Director Elena Ridloff sold 4,600 shares on April 1 at an average price of ~$85.42 (disclosed via SEC). Large director sales can create near-term selling pressure or signal personal liquidity needs. Ridloff sale (AmericanBankingNews)
• Negative Sentiment: Additional disclosures show Ridloff sold 7,400 shares on March 31 and the April 1 sale was also filed with the SEC. Total recent Ridloff sales amount to ~12,000 shares across the two trades. Ridloff SEC filing
• Negative Sentiment: COO Jeremy G. Chadwick disclosed multiple sales (7,600 on March 31 and 14,640 on April 1) totaling ~22,240 shares at ~\$85.4 average — a roughly double‑digit percentage reduction in his reported ownership. Senior‑exec selling of this size can weigh on sentiment. Chadwick SEC filing
• Negative Sentiment: Multiple independent reports aggregated these insider trades (InsiderTrades, MarketBeat), increasing transparency but also spotlighting the concentration of recent insider liquidity. InsiderTrades summary

Analysts Set New Price Targets

A number of research firms recently issued reports on KYMR. Leerink Partners lifted their price target on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a research note on Monday, December 8th. Bank of America upped their price objective on shares of Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a report on Monday, March 16th. They set a “buy” rating and a $110.00 price objective on the stock. Stifel Nicolaus set a $114.00 target price on shares of Kymera Therapeutics in a research report on Monday, December 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $118.90.

Institutional Trading of Kymera Therapeutics

Several large investors have recently made changes to their positions in the company. Federated Hermes Inc. purchased a new position in Kymera Therapeutics in the 3rd quarter valued at $31,622,000. Hudson Bay Capital Management LP grew its holdings in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock worth $1,309,000 after buying an additional 18,134 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Kymera Therapeutics by 77.2% in the second quarter. China Universal Asset Management Co. Ltd. now owns 23,079 shares of the company’s stock valued at $1,007,000 after buying an additional 10,052 shares during the last quarter. Candriam S.C.A. raised its position in shares of Kymera Therapeutics by 24.4% in the third quarter. Candriam S.C.A. now owns 191,639 shares of the company’s stock valued at $10,847,000 after buying an additional 37,536 shares during the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in shares of Kymera Therapeutics by 272.7% in the second quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock worth $21,463,000 after buying an additional 359,847 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.